Determining the most appropriate components for a composite clinical trial outcome
- 31 October 2008
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 156 (4), 633-640
- https://doi.org/10.1016/j.ahj.2008.05.018
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass SurgeryCirculation, 2008
- Effect of Ramipril on the Incidence of DiabetesNew England Journal of Medicine, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2004
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995
- Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractionsThe Lancet, 1992
- The Acute Infarction Ramipril Efficacy (AIRE) StudyJournal of Cardiovascular Pharmacology, 1991
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986